Designing a First-in-Human Single-Ascending-Dose Study of a Once-Weekly Basal Insulin Analogue in Adults with Type 2 Diabetes: Dose Logic, Hypoglycemia Safeguards, and Phase 1 Protocol Synopsis

For a basal insulin engineered to act for a full week, the first human dose raises a problem that the usual first-in-human logic does not solve: a dose cannot be taken back, a glucose-lowering effect can persist for days, and a healthy volunteer has no hyperglycemia for the drug to treat. This article develops a hypothetical Phase 1 randomized single-ascending-dose study of a once-weekly acylated basal insulin analogue in adults with type 2 diabetes who already inject basal insulin, with an ultra-long-acting once-daily basal insulin as the active reference. It anchors four dose levels from 1.4 to 5.6 U/kg to the participants' own daily basal dose, with steps of 2.0-, 1.5-, and 1.33-fold, and it gates each cohort by sentinel dosing, a 72-hour observation, and a Safety Review Committee. The synopsis specifies 32 participants, 21 pharmacokinetic samples per participant to 42 days, continuous glucose monitoring, a graded hypoglycemia and rescue plan, and a descriptive statistical analysis. The article explains why a starting dose is tied to pharmacology instead of a toxicology no-effect level, and compares the design with healthy-volunteer and oncology first-in-human designs.Keywords: first-in-human; basal insulin analogue; once-weekly insulin; single ascending dose; hypoglycemia; continuous glucose monitoring; sentinel dosing; IND

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24426460
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Designing a First-in-Human Single-Ascending-Dose Study of a Once-Weekly Basal Insulin Analogue in Adults with Type 2 Diabetes: Dose Logic, Hypoglycemia Safeguards, and Phase 1 Protocol Synopsis

Peivand Pirouzi, Happy Makvana, Drashti Patel, Sahil Patel
Zenodo (CERN European Organization for Nuclear Research)
Diabetes Management and Research
article

Designing a First-in-Human Single-Ascending-Dose Study of a Once-Weekly Basal Insulin Analogue in Adults with Type 2 Diabetes: Dose Logic, Hypoglycemia Safeguards, and Phase 1 Protocol Synopsis

Peivand Pirouzi, Happy Makvana, Drashti Patel, Sahil Patel
article en

Abstract

For a basal insulin engineered to act for a full week, the first human dose raises a problem that the usual first-in-human logic does not solve: a dose cannot be taken back, a glucose-lowering effect can persist for days, and a healthy volunteer has no hyperglycemia for the drug to treat. This article develops a hypothetical Phase 1 randomized single-ascending-dose study of a once-weekly acylated basal insulin analogue in adults with type 2 diabetes who already inject basal insulin, with an ultra-long-acting once-daily basal insulin as the active reference. It anchors four dose levels from 1.4 to 5.6 U/kg to the participants' own daily basal dose, with steps of 2.0-, 1.5-, and 1.33-fold, and it gates each cohort by sentinel dosing, a 72-hour observation, and a Safety Review Committee. The synopsis specifies 32 participants, 21 pharmacokinetic samples per participant to 42 days, continuous glucose monitoring, a graded hypoglycemia and rescue plan, and a descriptive statistical analysis. The article explains why a starting dose is tied to pharmacology instead of a toxicology no-effect level, and compares the design with healthy-volunteer and oncology first-in-human designs.Keywords: first-in-human; basal insulin analogue; once-weekly insulin; single ascending dose; hypoglycemia; continuous glucose monitoring; sentinel dosing; IND

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Designing a First-in-Human Single-Ascending-Dose Study of a Once-Weekly Basal Insulin Analogue in Adults with Type 2 Diabetes: Dose Logic, Hypoglycemia Safeguards, and Phase 1 Protocol Synopsis — Peivand Pirouzi, Happy Makvana, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS